JP2026041756A5 - - Google Patents

Info

Publication number
JP2026041756A5
JP2026041756A5 JP2025193397A JP2025193397A JP2026041756A5 JP 2026041756 A5 JP2026041756 A5 JP 2026041756A5 JP 2025193397 A JP2025193397 A JP 2025193397A JP 2025193397 A JP2025193397 A JP 2025193397A JP 2026041756 A5 JP2026041756 A5 JP 2026041756A5
Authority
JP
Japan
Prior art keywords
antibody
chain
hcdr
region
lcdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025193397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026041756A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/015534 external-priority patent/WO2021155028A1/en
Application filed filed Critical
Publication of JP2026041756A publication Critical patent/JP2026041756A/ja
Publication of JP2026041756A5 publication Critical patent/JP2026041756A5/ja
Pending legal-status Critical Current

Links

JP2025193397A 2020-01-29 2025-11-13 抗mdr1抗体およびその使用 Pending JP2026041756A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062967470P 2020-01-29 2020-01-29
US62/967,470 2020-01-29
US202063085818P 2020-09-30 2020-09-30
US63/085,818 2020-09-30
PCT/US2021/015534 WO2021155028A1 (en) 2020-01-29 2021-01-28 Anti-mdr1 antibodies and uses thereof
JP2022545429A JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022545429A Division JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2026041756A JP2026041756A (ja) 2026-03-10
JP2026041756A5 true JP2026041756A5 (enExample) 2026-05-14

Family

ID=74673398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545429A Active JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用
JP2025193397A Pending JP2026041756A (ja) 2020-01-29 2025-11-13 抗mdr1抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022545429A Active JP7815595B2 (ja) 2020-01-29 2021-01-28 抗mdr1抗体およびその使用

Country Status (10)

Country Link
US (1) US12692311B2 (enExample)
EP (1) EP4097134A1 (enExample)
JP (2) JP7815595B2 (enExample)
KR (1) KR20220133884A (enExample)
CN (1) CN115023443A (enExample)
AU (1) AU2021214370A1 (enExample)
BR (1) BR112022013870A2 (enExample)
CA (1) CA3164608A1 (enExample)
MX (1) MX2022009355A (enExample)
WO (1) WO2021155028A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
KR20240116829A (ko) * 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2024235133A1 (zh) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 多环类药物偶联物及其制备方法和用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025232118A1 (zh) * 2024-05-10 2025-11-13 四川科伦博泰生物医药股份有限公司 稠环类化合物及其制备方法和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP2564412B2 (ja) 1990-03-02 1996-12-18 財団法人癌研究会 薬剤耐性癌に対するキメラ抗体およびその製造
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5948647A (en) 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
EP1865987A2 (en) 2005-04-06 2007-12-19 Cedars-Sinai Medical Center Inhibition of p-glycoprotein by treatment with a class of modulators and the uic2 monoclonal antibody
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110658340B (zh) 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체

Similar Documents

Publication Publication Date Title
CN112574307B (zh) 抗人Claudin18.2抗体及其应用
CN115551888B (zh) 抗cd73抗体及其用途
JP2024522360A5 (enExample)
CN112135626A (zh) 抗tigit抗体及其用途
JP2021524478A5 (enExample)
JP2022533538A5 (enExample)
RU2018124602A (ru) Новые анти-pd-l1 антитела
JP2024506315A5 (enExample)
RU2012112829A (ru) Анти-gitr-антитела
JP2023540526A5 (enExample)
JP2022527860A5 (enExample)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2022539589A5 (enExample)
JP2023528416A5 (enExample)
CN115785268B (zh) 抗cd47抗体及其用途
JP2025505650A5 (enExample)
JP2025508317A5 (enExample)
JP7653532B2 (ja) 抗Siglec15抗体およびその使用
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
JP2022547718A5 (enExample)
CN119176874A (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
CN112805297B (zh) 抗人类pd-l1抗体及其用途
JP2022527790A5 (enExample)
JP2025513714A5 (enExample)
CN119285774A (zh) 抗人tigit单克隆抗体tigit-m007或其功能性片段及其应用